Author
Listed:
- Meredith Y. Smith
(Evidera, Inc.
University of Southern California)
- Elaine H. Morrato
(Loyola University Chicago)
- Nallely Mora
(Loyola University Chicago)
- Viviana Nguyen
(Evidera, Inc.)
- Hilary Pinnock
(Usher Institute, University of Edinburgh)
- Almut G. Winterstein
(University of Florida)
Abstract
Introduction The Reporting recommendations Intended for pharmaceutical risk Minimization Evaluation Studies (RIMES) was developed to improve the quality of reporting of risk minimization program evaluations. In light of continued inadequacies in study reporting, and high-profile program implementation failures, we updated the RIMES Checklist to incorporate additional concepts from the Standards for Reporting of Implementation studies (StaRI). Methods The development of the updated checklist, the RIMES-StaRI Extension (RIMES-SE), entailed developing a study protocol and drafting an initial pool of items based on a mapping of the RIMES against the StaRI checklist. A modified e-Delphi exercise was then conducted to determine the importance and understandability of items for checklist inclusion. An expert workshop and an online commentary period for additional feedback followed. Results The RIMES-SE contains 27 items. It includes two signature features of the StaRI Checklist: 1) a dual strand of items (represented in two columns) describing the risk minimization program (the ‘intervention’) and the corresponding implementation strategy; and 2) applicable to an array of different research methodologies. Conclusions The RIMES-SE Statement and Checklist extends the reporting guidelines set forth in the original RIMES Checklist via inclusion of key implementation science concepts. It is intended to improve the quality and transparency of reporting of risk minimization evaluation studies so as to advance drug safety science.
Suggested Citation
Meredith Y. Smith & Elaine H. Morrato & Nallely Mora & Viviana Nguyen & Hilary Pinnock & Almut G. Winterstein, 2024.
"The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE),"
Drug Safety, Springer, vol. 47(7), pages 655-671, July.
Handle:
RePEc:spr:drugsa:v:47:y:2024:i:7:d:10.1007_s40264-024-01417-5
DOI: 10.1007/s40264-024-01417-5
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:47:y:2024:i:7:d:10.1007_s40264-024-01417-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.